Tracer library / [68Ga]PSMA-1-DOTA
[68Ga]PSMA-1-DOTA
- Radionuclide
- Ga-68 t½ 67.71 min
- Modality
- PET
- Production route
- —
- Stage
- Clinical research
- Syntheses indexed
- 1
What it is
- Compound class
- PSMA-targeting urea-based ligand conjugated to DOTA chelator
- Target / mechanism
- PSMA (prostate-specific membrane antigen) PMID 40897948
- Clinical application
- PET imaging of metastatic castration-resistant prostate cancer (compassionate use) PMID 40897948
- Theranostic pair
- [177Lu]Lu-PSMA-1-DOTA
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Scintomics GRP / GRP-3V Scintomics | vendor cassette | SPE | ~55% decay-corrected | >98% | PSMA-1-DOTA | 40897948 2025 Mol Imaging Biol The entire synthesis, including elution of radioactive gallium from the generator with 0.1 M hydrochloric acid, conjugation with PSMA-1 peptide, purification and formulation of the final product are automated by Scintomics GRP\u00ae synthesizer and controlled by the software using GMP-manufactured single-use sterile cassettes. - a typical decay corrected chemical yield of ~ 55% (~ 45% non-decay corrected at EOS) |
Need this precursor?We can point you to suppliers for [68Ga]PSMA-1-DOTA, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40897948. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40897948: 'PSMA-1-DOTA was synthesized on solid phase by Fmoc-chemistry as reported previously at 0.1 mmol scale [26].'. Stage set/updated at stage 23 from PMID 40897948: 'A compassionate use PET imaging study on a patient with metastatic castration-resistant prostate cancer was performed using [68 Ga]Ga-PSMA-1-DOTA.'. | Stage 30 (2026-09-18): Stage was 'compassionate use'; normalised to 'Clinical research', original wording kept here. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to PET: Ga-68 is a positron emitter used only for PET imaging. Linked articles: PMID 40897948.